IDEAYA Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
IDYA$31.75-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Collaboration revenue | $10,242 | $207,834 | $25,660 | $207,834 |
| Total revenue | 10,242 | 207,834 | 25,660 | 207,834 |
| Operating expenses | ||||
| Research and development | 121,576 | 82,993 | 325,991 | 228,105 |
| General and administrative | 26,298 | 16,389 | 68,135 | 44,472 |
| Total operating expenses | 147,874 | 99,382 | 394,126 | 272,577 |
| Loss from operations | (137,632) | 108,452 | (368,466) | (64,743) |
| Other income | ||||
| Interest income and other income, net | 11,883 | 10,792 | 31,726 | 34,318 |
| Net income (loss) | $(125,749) | $119,244 | $(336,740) | $(30,425) |
| Unrealized (losses) gains on marketable securities | (3,214) | 531 | (7,151) | 1,240 |
| Comprehensive income (loss) | $(128,963) | $119,775 | $(343,891) | $(29,185) |
| Net income (loss) per common share, basic | $(1.22) | $1.35 | $(3.56) | $(0.34) |
| Weighted-average common shares outstanding, basic | 102,944,175 | 88,526,781 | 94,620,638 | 88,452,395 |
| Net income (loss) per common share, diluted | $(1.22) | $1.33 | $(3.56) | $(0.34) |
| Weighted-average common shares outstanding, diluted | 102,944,175 | 89,690,878 | 94,620,638 | 88,452,395 |
(in thousands, except share amounts)
| Accumulated | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||||||||
| Shares · Amount · Capital · Income (Loss) · Deficit · Equity | ||||||||||||
| Balances as of June 30, 2026 | 96,375,637 | $10 | $2,148,095 | $(1,670) | $(947,530) | $1,198,905 | ||||||
| Issuance costs related to at-the-market offering program | — | — | (163) | — | — | (163) | ||||||
| Issuance costs related to public offering | — | — | (64) | — | — | (64) | ||||||
| Issuance of common stock upon exercise of stock options | 274,341 | — | 4,618 | — | — | 4,618 | ||||||
| Stock-based compensation | — | — | 17,730 | — | — | 17,730 | ||||||
| Other comprehensive loss | — | — | — | (3,214) | — | (3,214) | ||||||
| Net loss | — | (125,749) | (125,749) | |||||||||
| Balances as of September 30, 2026 | 96,649,978 | $10 | $2,170,216 | $(4,884) | $(1,073,279) | $1,092,063 | ||||||
| Balances as of June 30, 2025 | 87,641,776 | 9 | $9 | $1,730,633 | $1,521 | $(772,510) | $959,653 | |||||
| Issuance of common stock related to at-the-market offering program, net of issuance costs | 24,632 | — | (84) | — | — | (84) | ||||||
| Issuance of common stock upon exercise of stock options | — | — | 473 | — | — | 473 | ||||||
| Stock-based compensation | — | — | 12,217 | — | — | 12,217 | ||||||
| Other comprehensive income | — | — | — | 531 | — | 531 | ||||||
| Net income | — | — | — | — | 119,244 | 119,244 | ||||||
| Balances as of September 30, 2025 | 87,666,408 | $9 | $1,743,239 | $2,052 | $(653,266) | $1,092,034 | ||||||
(in thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of December 31, 2025 | 87,796,561 | $9 | $1,757,197 | $2,267 | $(736,539) | $1,022,934 |
| Issuance of common stock upon follow-on public offering | 7,222,225 | 1 | 182,332 | — | — | 182,333 |
| Issuance of pre-funded warrants for the purchase of common stock | — | — | 141,000 | — | — | 141,000 |
| Issuance of common stock related to at-the-market offering program | 1,196,423 | — | 32,921 | — | — | 32,921 |
| Issuance of common stock upon exercise of stock options | 397,972 | — | 6,919 | — | — | 6,919 |
| Employee stock purchase plan (ESPP) purchase | 36,797 | — | 922 | — | — | 922 |
| Stock-based compensation | — | — | 48,925 | — | — | 48,925 |
| Other comprehensive loss | — | — | — | (7,151) | — | (7,151) |
| Net loss | — | — | — | — | (336,740) | (336,740) |
| Balances as of September 30, 2026 | 96,649,978 | $10 | $2,170,216 | $(4,884) | $(1,073,279) | $1,092,063 |
| Balances as of December 31, 2024 | 86,503,509 | $9 | $1,681,167 | $812 | $(622,841) | $1,059,147 |
| Issuance of common stock related to at-the-market offering program, net of issuance costs | 984,000 | — | 24,914 | — | — | 24,914 |
| Issuance of common stock upon exercise of stock options | 130,409 | — | 2,016 | — | — | 2,016 |
| Employee stock purchase plan (ESPP) purchase | 48,490 | — | 820 | — | — | 820 |
| Stock-based compensation | — | — | 34,322 | — | — | 34,322 |
| Other comprehensive income | — | — | — | 1,240 | — | 1,240 |
| Net loss | — | — | — | — | (30,425) | (30,425) |
| Balances as of September 30, 2025 | 87,666,408 | $9 | $1,743,239 | $2,052 | $(653,266) | $1,092,034 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.